Performance characteristics of two real-time PCR assays for quantification of hepatitis B virus DNA

Detection and quantification for hepatitis B virus (HBV) DNA has been an essential tool in the clinical setting. We aimed to assess clinical performance of the RealArt HBV TM PCR (RealArt) assay and the COBAS TaqMan HBV (COBAS) assay. Serum levels of HBV DNA in 146 treatment-naïve chronic HBV (CHB) Taiwanese patients (118 males, 47 HBeAg + ; mean age, 34.7±13.0 y) were determined by both assays. The detection rate by the RealArt assay was 85.6% (125/146), which was not significantly different from the COBAS assay (89.7%, 131/146). The detection rate was also not significantly different between both assays irrespective of HBeAg seropositivity. The 2 assays were also comparable regarding quantification rate (92.8%, 116/125 vs 93.1%, 122/131). There was a positive correlation in the 109 specimens measurable by both assays (r=0.94,p<0.001). The mean HBV DNA level measured by the COBAS assay was significantly higher than the RealArt assay (5.24±1.83 vs 4.79±2.09 log IU/ml, p<0.001). This study demonstrated that both RealArt and COBAS assays were comparable regarding clinical performance in HBV DNA measurement.

[1]  A. Mangia,et al.  The use of molecular assays in the management of viral hepatitis. , 2008, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[2]  Y. Liaw,et al.  Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update , 2008, Hepatology international.

[3]  Ming‐Lung Yu,et al.  Performance characteristics of a real-time RT-PCR assay for quantification of hepatitis C virus RNA in patients with genotype 1 and 2 infections , 2008, Clinical chemistry and laboratory medicine.

[4]  P. Loehrer,et al.  Risk of Hepatocellular Carcinoma Across a Biological Gradient of Serum Hepatitis B Virus DNA Level , 2007 .

[5]  J. Tsai,et al.  Early mortality in Taiwanese lamivudine-treated patients with chronic hepatitis B-related decompensation: evaluation of the model for end-stage liver disease and index scoring systems as prognostic predictors. , 2006, Clinical therapeutics.

[6]  J. Goedert,et al.  Real-Time PCR Assay for Detection and Quantification of Hepatitis B Virus Genotypes A to G , 2006, Journal of Clinical Microbiology.

[7]  Guan-Tarn Huang,et al.  Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. , 2006, JAMA.

[8]  M. Yuen,et al.  Comparison of the COBAS TaqMan™ HBV test with the COBAS Amplicor monitor™ test for measurement of hepatitis B virus DNA in serum , 2005, Journal of medical virology.

[9]  J. Tsai,et al.  Clinical evaluation of the COBAS Amplicor HBV monitor test for measuring serum HBV DNA and comparison with the Quantiplex branched DNA signal amplification assay in Taiwan , 2004, Journal of Clinical Pathology.

[10]  F. Rousseau,et al.  Serum HBV DNA as a marker of efficacy during therapy for chronic HBV infection: Analysis and review of the literature , 2003, Hepatology.

[11]  Ding-Shinn Chen,et al.  Global control of hepatitis B virus infection. , 2002, The Lancet. Infectious diseases.

[12]  Y. Liaw Management of patients with chronic hepatitis B , 2002, Journal of gastroenterology and hepatology.

[13]  B. McMahon,et al.  Chronic hepatitis B , 2001, Hepatology.

[14]  L. Y. Wang,et al.  The status of serum hepatitis B virus DNA in HBSAG-positive hepatocellular carcinoma. , 1996, The Kaohsiung journal of medical sciences.

[15]  R. Figueroa Barrios [Chronic hepatitis]. , 1995, Revista de gastroenterologia del Peru : organo oficial de la Sociedad de Gastroenterologia del Peru.

[16]  Ding‐Shinn Chen,et al.  From hepatitis to hepatoma: lessons from type B viral hepatitis. , 1993, Science.